Latest news
Why CAR T-Cell Therapy Should Precede Bispecifics in Multiple Myeloma - CancerNetworkCancerNetwork · Fri, 07 Aug 2026 15:09:51 GMTThe Impact of Bispecifics in Community Oncology Settings - Pharmacy TimesPharmacy Times · Thu, 06 Aug 2026 19:59:43 GMTThe Lowest-Ever Hazard Ratio in Multiple Myeloma Bispecific Trials? - CancerNetworkCancerNetwork · Thu, 06 Aug 2026 19:09:04 GMTAdverse Event Management for Bispecific Antibodies and CAR T-Cell Therapies in Relapsed/Refractory Multiple Myeloma - Pharmacy TimesPharmacy Times · Thu, 06 Aug 2026 12:42:09 GMTFrom Treatment to Prevention: How Pharmacists Are Refining CRS Management for Bispecific Antibody Therapy - Pharmacy TimesPharmacy Times · Wed, 05 Aug 2026 21:37:49 GMTLaura Alder: Registration Opens for "Bispecifics, ADCs and Beyond" - oncodaily.comoncodaily.com · Wed, 05 Aug 2026 19:08:35 GMTExpanding Community Access to CAR T, Bispecific Therapies in Multiple Myeloma: Peter Forsberg, MD - The American Journal of Managed Care® (AJMC®)The American Journal of Managed Care® (AJMC®) · Tue, 04 Aug 2026 20:37:17 GMTPfizer Plans Late-Stage Trials for ADCs, Bispecifics While Oncology Revenue Continues Growth - Precision Medicine OnlinePrecision Medicine Online · Tue, 04 Aug 2026 18:38:01 GMT